arrow
R

Renata Pacholczak-Madej

jagiellonian university medical college
H指数:13
被引数:473

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Enhanced thrombin generation potential in male and female patients with Fabry disease: a single-center observational study

法布里病患者中男性和女性促凝酶生成潜力的增强:一项单中心观察性研究

2026-08-210
OAAI
Vascular endothelial dysfunction and echocardiographic changes in male and female patients with Fabry disease: a single-center observational study

法布雷病患者中男性和女性患者的血管内皮功能障碍和超声心动图变化:一项单中心观察性研究

2026-08-120
OA
Immune-Related Adverse Events of Cemiplimab Therapy in Advanced Cervical Cancer—Data from the Polish–Czech Cervical Cancer Immunotherapy Group (PCCIG-01) with a Review of the Literature

cemiplimab疗法在晚期宫颈癌中的免疫相关不良事件—来自波兰-捷克宫颈癌免疫治疗组(PCCIG-01)的数据及文献综述

2026-05-190
OAAI
Efficacy and safety of sacituzumab govitecan in patients with metastatic metaplastic triple-negative breast cancer: a multinational retrospective case series from CEBCC-102 study

Sacituzumab govitecan在转移性化生性三阴性乳腺癌患者中的疗效与安全性:一项来自CEBCC-102研究的跨国回顾性病例系列研究

2025-12-090
OAAI
Sacituzumab Govitecan initial dose reduction in polish patients with metastatic triple-negative breast cancer: impact on efficacy and safety

Sacituzumab Govitecan在波兰转移性三阴性乳腺癌患者中的初始剂量降低:对疗效和安全性的影响

2025-10-040
OA
Strategies for premedication and G-CSF application in sacituzumab govitecan treatment of patients with triple-negative breast cancer: multicenter insights

曲拉妥珠单抗(sacituzumab govitecan)治疗三阴性乳腺癌患者的预用药及粒细胞集落刺激因子(G-CSF)应用策略:多中心见解

2025-09-280
OA
Effectiveness and safety of nivolumab and ipilimumab in older adults with renal cell carcinoma: findings from a multicenter observational study in Poland

纳武利尤单抗和伊匹木单抗在老年肾细胞癌患者中的有效性与安全性:来自波兰一项多中心观察性研究的结果

2025-08-230
OA
Validation of the EORTC information (QLQ-INFO25) and satisfaction with care (IN-PATSAT32) modules in the Polish cancer patient population

EORTC信息(QLQ-INFO25)和护理满意度(IN-PATSAT32)模块在波兰癌症患者人群中的验证

2025-02-130
OA
Prognostic significance of peripheral blood biomarkers in patients with advanced renal cell carcinoma treated with nivolumab and ipilimumab-a polish multicenter, observational study
2025-01-230
OAAI
Time from Final Oncologist Visit to Death and Palliative Systemic Treatment Use Near the End of Life in Heavily Pretreated Patients with Luminal Breast Cancer

在经过大量预处理的管腔乳腺癌患者中,从最终的肿瘤科医生就诊到死亡和姑息性全身治疗的时间接近生命的终点

2024-11-080
OAAI
Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Results of Polish multicenter observational study

Nivolumab在头颈部复发或转移性鳞状细胞癌患者中的应用: 波兰多中心观察性研究的结果

2024-11-050
OA
Sacituzumab Govitecan for Second and Subsequent Line Palliative Treatment of Patients with Triple-Negative Breast Cancer: A Polish Real-World Multicenter Cohort Study

Sacituzumab Govitecan用于三阴性乳腺癌患者的二线和后续姑息治疗: 一项波兰真实世界多中心队列研究

2024-09-270
OAAI